Jamie Platt
About Jamie Platt
Jamie Platt, Ph.D., age 58, is an independent director of bioAffinity Technologies (BIAF) appointed in December 2023. She is a genomics and molecular diagnostics executive with 20 years’ leadership experience developing, validating, and commercializing high‑complexity molecular tests, and holds a Ph.D. in molecular and cellular biology (Oregon State University) with post‑doctoral studies at UC Berkeley .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Personal Genome Diagnostics (acquired by Labcorp) | Chief Operations Officer | Aug 2021 – Apr 2023 | Led precision oncology operations |
| Inivata Limited (acquired by NeoGenomics) | Chief Operations Officer | Feb 2017 – Jan 2021 | Scaled liquid biopsy technology |
External Roles
| Organization | Role | Tenure | Board/Committees |
|---|---|---|---|
| Pictor Ltd (IVD) | Managing Director & Chief Executive Officer | Apr 2023 – Present | Director since Jan 2021 |
| BRIDGenomics (consulting/contract commercialization) | President & Chief Executive Officer | May 2015 – Present | — |
| DxTerity Diagnostics Inc. | Director | Mar 2021 – Present | Board member |
Board Governance
- Independence: The Board affirmatively determined Dr. Platt is independent under Nasdaq rules, including for committee service .
- Committees: Member, Compensation Committee (committee to consist of Peter Knight, Chair, and Jamie Platt following the 2025 Annual Meeting) .
- Chair roles: None disclosed for Dr. Platt .
- Attendance: In 2024, each current director attended at least 75% of Board and applicable committee meetings (includes Dr. Platt) .
- Years of service: Director since December 2023 .
- Governance policies: Company prohibits short sales and hedging by directors and employees via its Insider Trading Policy ; the Company has no formal director stock ownership guidelines, though ownership is encouraged via equity grants .
Fixed Compensation
| Metric | FY 2024 |
|---|---|
| Annual cash retainer (program design) | $25,000; paid quarterly |
| Committee chair fees (program design) | Audit Chair $5,000; Compensation Chair $2,500; Nominating Chair $2,500; paid quarterly |
| Annual equity grant (program design) | Restricted stock ~ $75,000 grant date value; vests pro rata monthly over 12 months |
| Fees Earned or Paid in Cash (actual) | $26,875 |
| Stock Awards – grant date fair value (actual) | $112,498 |
| Total Director Compensation (actual) | $139,373 |
Performance Compensation
- Structure: Directors receive time‑based restricted stock vesting monthly; no performance‑based metrics are disclosed for director pay . | Grant Type | FY 2024 | Vesting Terms | |---|---|---| | Restricted Stock (Director annual equity) | $112,498 grant‑date fair value | Vests pro rata monthly over 12 months |
Other Directorships & Interlocks
| Company | Relationship to BIAF | Potential Interlock/Conflict |
|---|---|---|
| Pictor Ltd (IVD) | External CEO and director | Same broad diagnostics industry; no related‑party transactions with BIAF disclosed |
| DxTerity Diagnostics Inc. | External director | Diagnostics; no related‑party transactions with BIAF disclosed |
Expertise & Qualifications
- Scientific/technical expertise: Led development, validation, and commercialization of 40+ high‑complexity molecular tests (LDTs and IVDs) .
- Board experience: Director roles at Pictor and DxTerity; CEO roles in diagnostics and consulting, indicating commercialization and scaling experience .
- Credentials: Ph.D. in molecular & cellular biology; post‑doctoral studies at UC Berkeley; patents and peer‑reviewed publications; industry speaker .
Equity Ownership
| As of Date | Shares Beneficially Owned | % of Class | Notes |
|---|---|---|---|
| May 29, 2025 | 54,748 | <1% | Issued as restricted stock; includes 5,634 unvested restricted shares (has voting rights, not dispositive rights) |
| Nov 4, 2025 | 1,824 | <1% | Issued as restricted stock (share count reflects post‑corporate actions) |
- Pledging/Hedging: Company policy prohibits short sales and hedging; pledging not specifically referenced; no pledging by Dr. Platt disclosed .
- Ownership guidelines: No formal director stock ownership guidelines; equity grants encourage alignment .
Governance Assessment
-
Positive signals
- Independent director with relevant diagnostics operating experience; sits on Compensation Committee overseeing executive pay structures .
- 2024 attendance at or above minimum expectations, supporting engagement .
- Director compensation includes meaningful equity grants that vest over time, promoting ownership alignment .
- Insider Trading Policy restricts hedging/shorting, supporting alignment and risk controls .
- No related‑party transactions involving Dr. Platt disclosed, reducing conflict risk .
-
Watch items / potential conflicts
- External CEO role in diagnostics (Pictor) and board role at DxTerity imply overlapping sector exposure; monitor for any business dealings, competitive overlap, or information-sharing risks; none disclosed to date .
- Lack of formal director stock ownership guidelines could weaken long‑term alignment versus best practice; consider voluntary targets or enhanced disclosure .
- Expanded equity plan capacity (2024 Plan amendment to 750,000 shares proposed in the 2025 special meeting) increases potential equity overhang; monitor grant practices and dilution impact on alignment .
-
Compensation structure integrity
- No performance metrics tied to director compensation are disclosed; design relies on fixed cash retainers plus time‑based equity—typical for small‑cap governance but merits oversight to ensure pay remains proportional to effort and outcomes .
-
Compliance/insider filings
- Company indicates timely Section 16 filings in 2024/2023 with exceptions noted for other individuals; Dr. Platt not listed among exceptions, suggesting compliance .